Cancer cell killing via ROS: To increase or decrease, that is the question

Reactive oxygen species (ROS) act as a second messenger in cell signaling and are essential for various biological processes in normal cells. Any aberrance in redox balance may relate to human pathogenesis including cancers. Since ROS are usually increased in cancer cells due to oncogene activation, relative lack of blood supply or other variances, and ROS do involve in initiation, progression and metastasis of cancers, ROS are considered oncogenic. Ironically, ROS production is a mechanism shared by all non-surgical therapeutic approaches for cancers, including chemotherapy, radiotherapy and photodynamic therapy, due to their implication in triggering cell death, therefore ROS are also used to kill cancer cells. Because of the double-edged sword property of ROS in determining cell fate, both pro- or anti-oxidant therapies have been proposed for treatments of cancers. Based on either side, a number of drugs, agents and approaches are developed or in the progress of development, some of which have shown clinical promise. This review summarizes the current understanding on ROS-manipulation strategies in cancer treatment and underlying mechanisms. ROS-producing or -eliminating agents and the potential drugs in this aspect are categorized. An effort is made in particular to discuss the paradox in the rationales of two opposite ROS-manipulation strategies and the concerns for their use. Selectivity between tumor and non-tumor cells may depend on difference of their redox environments. A combinational set of cellular parameters including redox status, antioxidant enzymes expression, cell signaling and transcription factor activation profiles, namely "redox signaling signature", is waiting for being developed in order to choose ROS-elevating or ROS-depleting therapy specific to certain type of cancer cells. In clinical setting individualized choice of an optimal ROS-manipulation therapy may require an accurate and convenient measurements for ROS as well as "redox signaling signature" for prediction of efficacy and systemic toxicity.

[1]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[2]  A. Levitzki,et al.  ROS, stress‐activated kinases and stress signaling in cancer , 2002, EMBO reports.

[3]  G. Mantovani,et al.  Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. , 2003, Journal of experimental therapeutics & oncology.

[4]  M. Hashida,et al.  PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. , 2006, Free radical biology & medicine.

[5]  A. Holmgren,et al.  The thioredoxin system in cancer. , 2006, Seminars in cancer biology.

[6]  M. Madesh,et al.  VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release , 2001, The Journal of cell biology.

[7]  Daniel F. Brayton,et al.  Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. , 2004, Journal of medicinal chemistry.

[8]  S. Kimura,et al.  A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo , 2006, British Journal of Cancer.

[9]  R. Carroll,et al.  Differential Response to DNA Damage May Explain Different Cancer Susceptibility Between Small and Large Intestine , 2005, Experimental biology and medicine.

[10]  M. Toledano,et al.  ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis , 2007, Nature Reviews Molecular Cell Biology.

[11]  M. Murphy,et al.  A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF‐1α , 2005, FEBS letters.

[12]  R. Kramer,et al.  Role of the glutathione redox cycle in acquired and de novo multidrug resistance. , 1988, Science.

[13]  K. Lillehei,et al.  A threshold concept for cancer therapy. , 2000, Medical hypotheses.

[14]  N. Sharpless,et al.  ROS as a tumour suppressor? , 2006, Nature Cell Biology.

[15]  Olivier Soubrane,et al.  Controlling tumor growth by modulating endogenous production of reactive oxygen species. , 2005, Cancer research.

[16]  T. Kamata,et al.  NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression , 2008, Oncogene.

[17]  K. Lillehei,et al.  Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats , 1998, Journal of surgical oncology.

[18]  J. Hayashi,et al.  ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis , 2008, Science.

[19]  S. Waxman,et al.  Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. , 1999, Blood.

[20]  Liying Wang,et al.  Regulation of Fas (CD95)‐induced apoptotic and necrotic cell death by reactive oxygen species in macrophages , 2005, Journal of cellular physiology.

[21]  V. Adhami,et al.  Beneficial effects of tea and its polyphenols against prostate cancer. , 2006, Molecular nutrition & food research.

[22]  H. Vainio,et al.  Wine and resveratrol: mechanisms of cancer prevention? , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[23]  V. Gladyshev,et al.  Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma Cells* , 2006, Journal of Biological Chemistry.

[24]  S. K. Choudhuri,et al.  A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo , 2006, BMC Cancer.

[25]  W. Fiers,et al.  More than one way to die: apoptosis, necrosis and reactive oxygen damage , 1999, Oncogene.

[26]  S. Agarwala,et al.  Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment , 2001, Expert opinion on biological therapy.

[27]  L. Oberley,et al.  Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells , 2005, Oncogene.

[28]  S. Mader,et al.  Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines , 2003, Leukemia.

[29]  Jie Yang,et al.  Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. , 2006, Free radical biology & medicine.

[30]  G. D’Andrea.  Use of Antioxidants During Chemotherapy and Radiotherapy Should Be Avoided , 2005, CA: a cancer journal for clinicians.

[31]  T. Xu,et al.  Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. , 2007, Toxicology and applied pharmacology.

[32]  F. Marshall,et al.  Increased Nox1 and hydrogen peroxide in prostate cancer , 2005, The Prostate.

[33]  Jidong Cheng,et al.  Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Emodin , 2002, Japanese journal of cancer research : Gann.

[34]  Jie Wang,et al.  Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: The mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1 , 2008, Cancer biology & therapy.

[35]  G. Kroemer,et al.  Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis , 2000, Oncogene.

[36]  J. Mitsushita,et al.  Nox1 Redox Signaling Mediates Oncogenic Ras-induced Disruption of Stress Fibers and Focal Adhesions by Down-regulating Rho* , 2007, Journal of Biological Chemistry.

[37]  Brian J. Smith,et al.  Suppression of the malignant phenotype in pancreatic cancer by overexpression of phospholipid hydroperoxide glutathione peroxidase. , 2006, Human gene therapy.

[38]  F. Meyskens,et al.  UC Irvine UC Irvine Previously Published Works Title Reactive oxygen species : a breath of life or death ? , 2007 .

[39]  G. Giles.  The redox regulation of thiol dependent signaling pathways in cancer. , 2006, Current pharmaceutical design.

[40]  Jürgen Hescheler,et al.  Reactive oxygen species‐linked regulation of the multidrug resistance transporter P‐glycoprotein in Nox‐1 overexpressing prostate tumor spheroids , 2005, FEBS letters.

[41]  J. Milner,et al.  A review of the interaction among dietary antioxidants and reactive oxygen species. , 2007, The Journal of nutritional biochemistry.

[42]  T. Galeotti,et al.  Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS) , 2006, Oncogene.

[43]  P. Chiarugi.  ReviewPTPs versus PTKs: The redox side of the coin , 2005, Free radical research.

[44]  F. Gao,et al.  The endogenous reactive oxygen species promote NF-kappaB activation by targeting on activation of NF-kappaB-inducing kinase in oral squamous carcinoma cells. , 2007, Free radical research.

[45]  A. Evens,et al.  Oxidative stress and apoptosis: a new treatment paradigm in cancer. , 2006, Frontiers in bioscience : a journal and virtual library.

[46]  P. Schumacker,et al.  Reactive oxygen species in cancer cells: live by the sword, die by the sword. , 2006, Cancer cell.

[47]  X. Hua,et al.  Targeting ROS: Selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound , 2007, Cancer Biology & Therapy.

[48]  M. Ushio-Fukai,et al.  Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. , 2008, Cancer letters.

[49]  Zvulun Elazar,et al.  ROS, mitochondria and the regulation of autophagy. , 2007, Trends in cell biology.

[50]  D. Häussinger,et al.  Involvement of NADPH Oxidase Isoforms and Src Family Kinases in CD95-dependent Hepatocyte Apoptosis* , 2005, Journal of Biological Chemistry.

[51]  N. Holbrook,et al.  Cellular response to oxidative stress: Signaling for suicide and survival * , 2002, Journal of cellular physiology.

[52]  X. Shi,et al.  The inherent cellular level of reactive oxygen species: One of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide , 2002, Apoptosis.

[53]  G. Cottrell,et al.  c-Cbl Mediates Ubiquitination, Degradation, and Down-regulation of Human Protease-activated Receptor 2* , 2005, Journal of Biological Chemistry.

[54]  M. Krainer,et al.  Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. , 2007, The international journal of biochemistry & cell biology.

[55]  You-Sun Kim,et al.  TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. , 2007, Molecular cell.

[56]  M. Mccarty,et al.  A two-phase strategy for treatment of oxidant-dependent cancers. , 2007, Medical hypotheses.

[57]  Z. Elazar,et al.  Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4 , 2007, The EMBO journal.

[58]  R. Ye,et al.  Emodin Enhances Arsenic Trioxide-Induced Apoptosis via Generation of Reactive Oxygen Species and Inhibition of Survival Signaling , 2004, Cancer Research.

[59]  K. Conklin.  Dietary Antioxidants During Cancer Chemotherapy: Impact on Chemotherapeutic Effectiveness and Development of Side Effects , 2000, Nutrition and cancer.

[60]  T. Hasan,et al.  Targeted photodynamic therapy , 2006, Lasers in surgery and medicine.

[61]  Hui-Yi Lin,et al.  Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. , 2002, Biochemical pharmacology.

[62]  Z. Elazar,et al.  Oxidation as a Post-Translational Modification that Regulates Autophagy , 2007, Autophagy.

[63]  Ssang-Goo Cho,et al.  Negative Regulation of MEKK1-induced Signaling by Glutathione S-Transferase Mu* , 2004, Journal of Biological Chemistry.

[64]  Toshiyuki Fukada,et al.  Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. , 2002, Molecular cell.

[65]  H. Chung,et al.  Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine-induced cytotoxicity in HepG2 cells , 2004, Archives of pharmacal research.

[66]  Barry Halliwell,et al.  Oxidative stress and cancer: have we moved forward? , 2007, The Biochemical journal.

[67]  W. Plunkett,et al.  Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. , 2003, Blood.

[68]  M. Hashida,et al.  Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[69]  M. Ochi,et al.  Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[70]  H. Shimizu,et al.  Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. , 2004, The American journal of pathology.

[71]  H. Naderi-manesh,et al.  Brevinin-2R1 semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway , 2008, Journal of cellular and molecular medicine.

[72]  M. Hashida,et al.  SOD derivatives prevent metastatic tumor growth aggravated by tumor removal , 2008, Clinical & Experimental Metastasis.

[73]  M. Kizaki,et al.  Induction of apoptosis via the modulation of reactive oxygen species (ROS) production in the treatment of myeloid leukemia. , 2006, Current pharmaceutical biotechnology.

[74]  K. Lillehei,et al.  Antioxidant inhibitors for cancer therapy. , 1998, Medical hypotheses.

[75]  Peter Greenwald,et al.  The antioxidant conundrum in cancer. , 2003, Cancer research.

[76]  H. Wu,et al.  Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. , 2008, Neoplasia.

[77]  M. Renschler.  The emerging role of reactive oxygen species in cancer therapy. , 2004, European journal of cancer.

[78]  G. Grunwald,et al.  The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. , 2006, Free radical biology & medicine.

[79]  T. Denning,et al.  Oxidative stress induces the expression of Fas and Fas ligand and apoptosis in murine intestinal epithelial cells. , 2002, Free radical biology & medicine.

[80]  Quan Fang,et al.  Are peroxiredoxins tumor suppressors? , 2007, Current opinion in pharmacology.

[81]  D. Mottet,et al.  Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. , 2002, Free radical biology & medicine.

[82]  Yong J. Lee,et al.  Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. , 2003, The Biochemical journal.

[83]  S. Javadov,et al.  Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. , 2004, Cardiovascular research.

[84]  A. Levine,et al.  The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.

[85]  T. Furukawa,et al.  Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. , 2008, Carcinogenesis.

[86]  Richard A. Miller,et al.  The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy , 2005, Cancer biology & therapy.

[87]  P. Chang,et al.  Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[88]  Y. Nagakawa,et al.  Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[89]  K. Lillehei,et al.  Intralesionally implanted cisplatin cures primary brain tumor in rats , 1997, Journal of surgical oncology.

[90]  Cynthia Cohen,et al.  Reactive oxygen generated by Nox1 triggers the angiogenic switch , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[91]  D. Noe,et al.  Selective enhancement of cellular oxidative stress by chloroquine: implications for the treatment of glioblastoma multiforme. , 2006, Neurosurgical focus.

[92]  D. Shaw,et al.  Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224) , 2008, British Journal of Cancer.

[93]  P. Gee,et al.  c-Cbl-mediated Ubiquitinylation Is Required for Epidermal Growth Factor Receptor Exit from the Early Endosomes* , 2004, Journal of Biological Chemistry.

[94]  Patrizia Agostinis,et al.  Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. , 2007, Biochimica et biophysica acta.

[95]  K. Hellstrand.  Histamine in cancer immunotherapy: a preclinical background. , 2002, Seminars in oncology.

[96]  W. J. Esselman,et al.  Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. , 2002, Free radical biology & medicine.

[97]  W. Min,et al.  Thioredoxin Promotes ASK1 Ubiquitination and Degradation to Inhibit ASK1-Mediated Apoptosis in a Redox Activity-Independent Manner , 2002, Circulation research.

[98]  Chih-Ching Wu,et al.  Subcellular localization of Photofrin® determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: When plasma membranes are the main targets , 2003, Journal of cellular physiology.

[99]  S. Pervaiz,et al.  Reactive oxygen species and the mitochondrial signaling pathway of cell death. , 2005, Histology and histopathology.

[100]  James B. Mitchell,et al.  The chemistry and biology of nitroxide compounds. , 2007, Free radical biology & medicine.

[101]  C. Dang,et al.  Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Jie Yang,et al.  Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. , 2004, Free radical biology & medicine.

[103]  T. Ozben.  Oxidative stress and apoptosis: impact on cancer therapy. , 2007, Journal of pharmaceutical sciences.

[104]  Peng Huang,et al.  ROS stress in cancer cells and therapeutic implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[105]  T. Cotter,et al.  Mechanisms of ROS modulated cell survival during carcinogenesis. , 2008, Cancer letters.